Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Assets Average (2022 - 2025)

Historic Assets Average for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $654.5 million.

  • Axsome Therapeutics' Assets Average rose 1796.47% to $654.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $654.5 million, marking a year-over-year increase of 1796.47%. This contributed to the annual value of $578.4 million for FY2024, which is 2577.13% up from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Assets Average is $654.5 million, which was up 1796.47% from $618.2 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Assets Average peaked at $654.5 million during Q3 2025, and registered a low of $134.6 million during Q2 2022.
  • Its 4-year average for Assets Average is $491.4 million, with a median of $559.9 million in 2024.
  • Per our database at Business Quant, Axsome Therapeutics' Assets Average skyrocketed by 27188.59% in 2023 and then crashed by 847.93% in 2024.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Assets Average stood at $335.2 million in 2022, then soared by 77.36% to $594.5 million in 2023, then fell by 4.97% to $565.0 million in 2024, then grew by 15.85% to $654.5 million in 2025.
  • Its last three reported values are $654.5 million in Q3 2025, $618.2 million for Q2 2025, and $582.6 million during Q1 2025.